V. Joly

发表

Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.

D. H. Kennedy, D. Hawkins, M. Moroni, 1999, International journal of antimicrobial agents.

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

Jacques Izopet, Diane Descamps, F. Brun-Vézinet, 2001, Journal of Virology.

Mycobacterium tuberculosis infections

P. Yeni, A. Hance, V. Joly, 1993 .

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir

F. Brun-Vézinet, J. Izopet, G. Peytavin, 2002, Journal of acquired immune deficiency syndromes.

Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome

Y. Yazdanpanah, L. Bouadma, F. Lescure, 2015, Infectious diseases.

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2004, Antimicrobial Agents and Chemotherapy.

Active tuberculosis does not always imply the initiation of highly active antiretroviral therapy in HIV-infected patients.

P. Yeni, V. Joly, C. Fortin, 2008, Journal of acquired immune deficiency syndromes.

Interest of cytology combined with Xpert® HPV and Anyplex® II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV‐infected patients on antiretroviral therapy

C. Charpentier, V. Joly, L. Abramowitz, 2018, HIV medicine.

Time to initiation of antiretroviral therapy in HIV‐infected patients diagnosed with an opportunistic disease: a cohort study

C. Sabin, Y. Yazdanpanah, H. Melliez, 2015, HIV medicine.

Use of a reamplification protocol improves sensitivity of detection of Mycobacterium tuberculosis in clinical samples by amplification of DNA

P. Yeni, A. Hance, V. Joly, 1991, Journal of clinical microbiology.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2014, The Journal of antimicrobial chemotherapy.

Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.

D. Costagliola, D. Descamps, V. Joly, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Abacavir has no prothrombotic effect on platelets in vitro.

A. Rauch, P. Yeni, V. Joly, 2016, The Journal of antimicrobial chemotherapy.

Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.

F. Raffi, P. Yeni, C. Maslo, 1996, The Journal of antimicrobial chemotherapy.

Upregulation of nerve growth factor expression by human airway smooth muscle cells in inflammatory conditions

N. Frossard, N. Martinet, F. Pons, 2002, European Respiratory Journal.

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Respiratory Medicine.

Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort

L. Cuzin, L. Cotte, V. Joly, 2017, AIDS (London).

Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.

C. Charpentier, F. Raffi, D. Descamps, 2014, The Journal of antimicrobial chemotherapy.

Septic thrombophlebitis of the portal vein.

Claude Carbón, A. Sibert, N. Belmatoug, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Useofa Reamplification Protocol Improves Sensitivity ofDetection ofMycobacterium tuberculosis inClinical Samples byAmplification ofDNA

P. Yeni, V. Joly, D. Lecossier, 1991 .

Pacemaker endocarditis due to Candida albicans: case report and review.

Claude Carbón, N. Belmatoug, P. Yeni, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nucleoside Analogue-Sparing Strategy for the Treatment of Chronic HIV Infection: Potential Interest and Clinical Experience

P. Yeni, V. Joly, 2005, Antiviral therapy.

Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture.

Claude Carbón, J. Bolard, P. Yeni, 1992, The Journal of infectious diseases.

Endocardites Coxiella burnetii sur prothse: six observations

Claude Carbón, O. Launay, V. Joly, 2001 .

Silicone in HIV-1-infected patients: a cause of misdiagnosed granulomatous disease.

H. Adle-Biassette, P. Yeni, N. Leboulanger, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4)

C. Katlama, H. Melliez, M. Guiguet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.

D. Descamps, O. Launay, V. Joly, 2002, Journal of acquired immune deficiency syndromes.

Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits

R. Farinotti, Claude Carbón, P. Yeni, 1996, Antimicrobial agents and chemotherapy.

Acute Lung, Heart, Liver, and Pancreatic Involvements with Hyponatremia and Retinochoroiditis in a 33-Year-Old French Guianan Patient

D. Aubert, I. Villena, M. Demar, 2012, PLoS neglected tropical diseases.

Lymphocyte subset counts during the course of community-acquired pneumonia: evolution according to age, human immunodeficiency virus status, and etiologic microorganisms.

J. Golmard, B. Fantin, P. Yeni, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study

Y. Yazdanpanah, F. Lescure, D. Descamps, 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

MRI Features Associated With the Detection of Microbial Pathogens by CT-Guided Biopsy in Septic Spondylodiscitis

Y. Yazdanpanah, H. Jacquier, P. Dieudé, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review

Y. Yazdanpanah, M. Wassef, N. Argy, 2020, Infection.

Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.

P. Yeni, I. Carrière, V. Joly, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Itraconazole oral solution for treatment of fluconazole resistant oral/esophageal candidosis in HIV-infected patients : Results of a prospective multicenter study. I. Clinical assessment

F. Raffi, B. Dupont, G. Nevez, 2008 .

Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.

Claude Carbón, P. Yeni, V. Joly, 1992, The American review of respiratory disease.

Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus.

S. Chevret, M. Wolff, E. Casalino, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tissue Distribution and Antifungal Effect of Liposomal Itraconazole in Experimental Cryptococcosis and

Claude Carbón, P. Yeni, V. Joly, 1991 .

Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.

Claude Carbón, P. Yeni, V. Joly, 1990, The Journal of pharmacology and experimental therapeutics.

In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis.

Claude Carbón, P. Yeni, V. Joly, 1994, The Journal of infectious diseases.

In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid

R. Farinotti, Claude Carbón, P. Yeni, 1994, Antimicrobial Agents and Chemotherapy.

Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses

M. Seman, Claude Carbón, P. Yeni, 1992, Antimicrobial Agents and Chemotherapy.

Mechanism of Action of Amphotericin B at the Cellular Level. Its Modulation by Delivery Systems

J. Bolard, P. Yeni, V. Joly, 1993 .

Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes.

Claude Carbón, P. Yeni, V. Joly, 1990, The Journal of infectious diseases.

Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats

Claude Carbón, P. Amirault, P. Yeni, 1991, Antimicrobial Agents and Chemotherapy.

Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.

Claude Carbón, P. Yeni, V. Joly, 1989, The Journal of pharmacology and experimental therapeutics.

In vitro models for studying toxicity of antifungal agents

J. Bolard, P. Yeni, V. Joly, 1992, Antimicrobial Agents and Chemotherapy.

Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations

Claude Carbón, J. Bolard, P. Yeni, 1992, Antimicrobial Agents and Chemotherapy.

In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.

J. Bolard, C. Petit, F. Gaboriau, 1998, The Journal of antimicrobial chemotherapy.

Influence of diet on experimental toxicity of amphotericin B deoxycholate

Claude Carbón, J. Bolard, P. Yeni, 1994, Antimicrobial Agents and Chemotherapy.

Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis

Claude Carbón, V. Joly, N. Chau, 1987, Antimicrobial Agents and Chemotherapy.

[Choice and monitoring of the treatment of systemic mycoses. Value and limitations of in vitro tests].

Claude Carbón, P. Yeni, V. Joly, 1992, Presse medicale.

MINIREVIEW InVitro ModelsforStudying Toxicity ofAntifungal Agents

J. Bolard, P. Yeni, V. Joly, 1992 .

A rare fungal infection: Phaehyphomycosis due to Veronaea botryosa and review of literature

N. Argy, V. Descamps, C. Chochillon, 2017, Medical mycology case reports.

Treatment of Latent Syphilis in HIV-infected Patients with 10 d of Benzylpenicillin G Benethamine: A Prospective Study in Maputo, Mozambique

P. Yeni, R. Bastos, P. Tattevin, 2002, Scandinavian journal of infectious diseases.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults

P. Yeni, V. Joly, C. Fortin, 2006, Expert opinion on emerging drugs.

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

P. Delobel, L. Cotte, M. Valantin, 2019, PloS one.

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

P. Yeni, V. Joly, P. Flandre, 2002, AIDS.

Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial

D. Hawkins, M. Moroni, Z. Bentwich, 2000, Antimicrobial Agents and Chemotherapy.

Efavirenz for HIV-1 infection in adults: an overview

V. Joly, C. Fortin, 2004, Expert review of anti-infective therapy.

Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.

Y. Yazdanpanah, F. Mechaï, J. Molina, 2022, Journal of acquired immune deficiency syndromes.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

A. Samri, D. Costagliola, G. Peytavin, 2016, The Journal of antimicrobial chemotherapy.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case–control study

C. Charpentier, Y. Yazdanpanah, M. Lê, 2017, The Journal of antimicrobial chemotherapy.

New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies.

V. Calvez, C. Katlama, J. Spano, 2020, The Journal of infectious diseases.

Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac.

Claude Carbón, V. Joly, B. Pangon, 1988, The Journal of pharmacology and experimental therapeutics.

Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy

Claude Carbón, V. Joly, B. Pangon, 1987, Antimicrobial Agents and Chemotherapy.

Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans

J. Mohler, Claude Carbón, V. Joly, 1987, Antimicrobial Agents and Chemotherapy.

Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.

E. Raymond, L. Sarda-Mantel, G. Peytavin, 2013, JAMA dermatology.

The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model.

Claude Carbón, V. Joly, B. Pangon, 1988, The Journal of antimicrobial chemotherapy.

Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine

R. Shafer, A. Zolopa, F. Clavel, 2005, Journal of acquired immune deficiency syndromes.

Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)–Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58

C. Charpentier, A. Couvelard, D. Descamps, 2018, The Journal of infectious diseases.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

C. Katlama, B. Hoen, F. Raffi, 2017, The Journal of antimicrobial chemotherapy.

Estimating and Comparing Reduction in HIV-1 RNA in Clinical Trials Using Methods for Interval Censored Data

D. Descamps, A. Alcais, V. Joly, 2004, Journal of acquired immune deficiency syndromes.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.

C. Charpentier, R. Tubiana, C. Katlama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases

V. Calvez, C. Katlama, N. Dupin, 2018, Journal of Clinical Microbiology.

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2004, The Journal of infectious diseases.

Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2003, Antiviral therapy.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

C. Katlama, F. Raffi, M. Hanf, 2018, PloS one.

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Rheumatology.

Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT’AIDS Study

I. Poizot-Martin, L. Hocqueloux, V. Joly, 2022, Open forum infectious diseases.

Association between renin–angiotensin–aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment

Y. Yazdanpanah, E. Vidal-Petiot, F. Lescure, 2020, Journal of hypertension.

Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2016, AIDS research and human retroviruses.

Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy.

Claude Carbón, D. Nochy, V. Joly, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.

D. Descamps, P. Yeni, V. Joly, 2002, AIDS reviews.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2019, The Journal of antimicrobial chemotherapy.

Endotoxin-tobramycin additive toxicity on renal proximal tubular cells in culture

M. Bergeron, Claude Carbón, Y. Bergeron, 1991, Antimicrobial Agents and Chemotherapy.

Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

F. Brun-Vézinet, D. Descamps, C. Goujard, 2002, Antimicrobial Agents and Chemotherapy.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

V. Calvez, C. Charpentier, C. Katlama, 2019, The Journal of antimicrobial chemotherapy.

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

C. Charpentier, C. Fagard, Y. Yazdanpanah, 2012, Antimicrobial Agents and Chemotherapy.

Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS

P. Morlat, F. Raffi, C. Leport, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.

L. Cuzin, F. Raffi, L. Hocqueloux, 2021, The Journal of antimicrobial chemotherapy.

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial

D. Benhamou, F. Brun-Vézinet, Y. Yazdanpanah, 2021, The Lancet.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

C. Katlama, Y. Yazdanpanah, C. Blanco-Betancourt, 2017, HIV medicine.

Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization

L. Cuzin, G. Martin-Blondel, P. Delobel, 2017, Journal of acquired immune deficiency syndromes.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

R. Breban, A. Samri, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

Philippe Flandre, Stéphane Rivet, Jean-Pierre Aboulker, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4)

D. Costagliola, Jean‐Marc Lacombe, M. Valantin, 2019, Journal of acquired immune deficiency syndromes.

Enfuvirtide: from basic investigations to current clinical use

P. Yeni, V. Joly, M. Tatay, 2010, Expert opinion on pharmacotherapy.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2013, PloS one.

18FDG-PET/CT: a useful tool for the management of patients in infectious diseases

Y. Yazdanpanah, L. Sarda-Mantel, F. Rouzet, 2017, Infectious diseases.

SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital

Y. Yazdanpanah, V. Joly, S. Le Gac, 2020, International Journal of Infectious Diseases.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

C. Charpentier, C. Fagard, F. Raffi, 2013, The Journal of antimicrobial chemotherapy.

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

P. Massip, J. Izopet, F. Mammano, 2001, Journal of virology.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, BMC Infectious Diseases.

Factors associated with being overweight and obesity in people living with HIV on antiretroviral therapy : socio-clinical, inflammation, and metabolic markers.

A. Maignan, Y. Yazdanpanah, D. Neau, 2021, The Journal of infectious diseases.

Isolated blepharoptosis may point to HIV-associated Burkitt’s lymphoma

J. Savatovsky, A. Moulignier, V. Joly, 2015, Acta Neurologica Belgica.

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Philippe Flandre, Françoise Brun-Vézinet, Diane Descamps, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Comparative evaluation over a six-month experience of postexposure antiretroviral treatment for occupational and non-occupational exposures to HIV

E. Casalino, V. Joly, S. Matheron, 1998 .